Biomarker Research
Cross-source consensus on Biomarker Research from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Evidence quality
Other
Highlighted claims
- Blood samples for biomarker assessment are collected on day 1 of cycles 1, 3, 5, and 7. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
- Biomarkers are exploratory endpoints in the trial. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
- The trial evaluates immune cells and VEGF levels to understand how induction treatment may enhance standard therapy. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
- Planned biomarker analyses examine links between antitumour effects and tumour microimmune changes, peripheral immune cells, and blood VEGF levels. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
- Optional tumour tissue samples are collected from consenting patients before treatment and after two cycles of atezolizumab plus nab-paclitaxel. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)